<DOC>
	<DOCNO>NCT02002377</DOCNO>
	<brief_summary>SHIFT-2 national , multi-center , non-randomized , open label trial aflibercept patient wet age relate macular degeneration incomplete response routineranibizumab treatment .</brief_summary>
	<brief_title>Intravitreal Aflibercept Wet Age Related Macular Degeneration Patients With Incomplete Response Routine Ranibizumab Injections</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Note : Subjects must meet follow inclusion criterion eligible enrollment study 1 . Age &gt; 50 year 2 . Active primary subfoveal choroidal neovascularization ( CNV ) lesion secondary AMD include juxtafoveal lesion affect fovea evidence Fluorescein Angiography study eye 3 . Presence intra sub retinal fluid SDOCT study eye 4 . Current treatment uninterrupted routine ( q35 +/ 7 day ) ranibizumab start least 3 month Baseline ( Week 0 ) , receive least 3 consecutive ranibizumab injection 24 injection maximum , ranibizumab injection interval 35 +/ 7 day apart 5 . ETDRS BCVA 20/30 20/320 ( letter score 78 25 ) study eye Subjects present follow include study : 1 . Presence purely serous pigment epithelial detachment study eye 2 . Any scarring fibrosis involve center fovea study eye 3 . Prior ocular systemic treatment/surgery wet AMD ranibizumab IVI monthly ( study eye ) 4 . Prior prn treat extend treatment ranibizumab IVI 3 24 month Baseline ( Week 0 ) study eye 5 . Prior treatment systemic antiVEGF therapy within last 6 month study eye 6 . History vitreous hemorrhage within last 6 month study eye 7 . Prior vitrectomy study eye 8 . History retinal detachment study eye 9 . History macular hole stage 2 study eye 10 . Presence retinal pigment epithelial tear rip involve macula study eye . 11 . Any intraocular periocular surgery/invasive procedure previous 6 month except lid surgery study eye 12 . Prior trabeculectomy filtration surgery study eye 13 . Uncontrolled glaucoma ( â‰¥ 25mmHg despite treatment antiglaucoma medication ) study eye 14 . Aphakia pseudophakia absence posterior capsule ( unless occur result yttrium aluminum garnet ( YAG ) posterior capsulotomy ) study eye . 15 . Scheduled intraocular surgery study period study eye 16 . Concurrent retinal disease ( i.e . diabetic retinopathy , retinal vein occlusion , retinal detachment , uveitis ) study eye 17 . History ocular periocular infection/inflammation study eye within last 4 week screen 18 . Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>51 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Age Related Macular Degeneration , wet</keyword>
	<keyword>aflibercept</keyword>
</DOC>